Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity-Reference-Cited by-同舟云学术

Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity

Published:2023-03-17 Issue:1 Volume:38 Page:
ISSN:1475-6366
Container-title:Journal of Enzyme Inhibition and Medicinal Chemistry
language:en
Short-container-title:Journal of Enzyme Inhibition and Medicinal Chemistry

Author:

El-Damasy Ashraf K.¹²,Jin Heewon¹,Park Jung Woo³,Kim Hyun Ji¹,Khojah Hanan⁴,Seo Seon Hee⁵,Lee Ju-Hyeon¹,Bang Eun-Kyoung¹,Keum Gyochang¹⁶

Affiliation:

1. Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea

2. Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt

3. Center for Supercomputing Applications, Div. of National Supercomputing R&D, Korea Institute of Science and Technology Information, Daejeon, Republic of Korea

4. Department of Pharmacognosy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia

5. Center for Brain Disorders, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea

6. Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology (UST), Seoul, Republic of Korea

Funder

National Research Council of Science & Technology

Korean government

Institutional Program grant by the Korea Institute of Science and Technology

the Korea Research Fellowship Program grant through NRF funded by the Ministry of Science and ICT

Korea Institute of Science and Technology Information (KISTI) Institutional Program

National Cancer Institute

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14756366.2023.2189097

Reference39 articles.

1. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

2. Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives

3. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

4. Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety

5. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering the Lexicon of Protein Targets: A Review on Multifaceted Drug Discovery in the Era of Artificial Intelligence;Molecular Pharmaceutics;2024-03-11

2. Dysregulated Signalling Pathways Driving Anticancer Drug Resistance;International Journal of Molecular Sciences;2023-07-30

3. Discovery of 3-((3-amino-1H-indazol-4-yl)ethynyl)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide (AKE-72), a potent Pan-BCR-ABL inhibitor including the T315I gatekeeper resistant mutant;Journal of Enzyme Inhibition and Medicinal Chemistry;2023-07-20